Get the Stockscreener App
8.12
2.29%
-0.19
Journey Medical Corp stock is traded at $8.12, with a volume of 153.39K.
It is down -2.29% in the last 24 hours and up +14.04% over the past month.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
See More
Previous Close:
$8.31
Open:
$8.16
24h Volume:
153.39K
Relative Volume:
0.97
Market Cap:
$164.92M
Revenue:
$56.13M
Net Income/Loss:
$-14.67M
P/E Ratio:
-10.97
EPS:
-0.74
Net Cash Flow:
$-9.13M
1W Performance:
+8.85%
1M Performance:
+14.04%
6M Performance:
+9.43%
1Y Performance:
+41.22%
1-Day Range:
$8.00
$8.39
1-Week Range:
$7.38
$8.39
52-Week Range:
$3.535
$8.8999
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
8.12 | 218.63M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | H.C. Wainwright | Buy |
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Journey Medical Corporation (NASDAQ:DERM) Given Average Rating of "Hold" by Brokerages - MarketBeat
Can a trend reversal in Journey Medical Corporation lead to recoveryPortfolio Risk Summary & Safe Entry Trade Signal Reports - newser.com
Health Equity - AstraZeneca
Why Journey Medical Corporation stock is recommended by analysts2025 Trading Volume Trends & Weekly Top Gainers Alerts - newser.com
Heatmap analysis for Journey Medical Corporation and competitorsJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Analyzing Journey Medical Corporation with multi timeframe chartsOil Prices & Short-Term High Return Ideas - newser.com
Price momentum metrics for Journey Medical Corporation explainedJuly 2025 Macro Moves & Weekly High Return Stock Forecasts - newser.com
How Journey Medical Corporation stock reacts to Fed rate cuts2025 Technical Overview & Free Fast Entry Momentum Trade Alerts - newser.com
Will Quipt Home Medical Corp. stock outperform value stocksWall Street Watch & Daily Stock Momentum Reports - Fundação Cultural do Pará
Short interest data insights for Journey Medical CorporationJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
Published on: 2025-10-27 18:20:54 - fcp.pa.gov.br
How Netflix Inc. stock performs in weak economyJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - fcp.pa.gov.br
Automated trading signals detected on Journey Medical CorporationPortfolio Performance Summary & Technical Confirmation Trade Alerts - newser.com
Using RSI to spot recovery in Journey Medical CorporationPortfolio Value Summary & Advanced Swing Trade Entry Alerts - newser.com
Will Journey Medical Corporation stock see insider buying2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Volatility clustering patterns for Journey Medical CorporationNew Guidance & AI Driven Stock Movement Reports - newser.com
Journey Medical (NASDAQ:DERM) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Journey Medical’s Emrosi shows superior efficacy for rosacea - Investing.com
Houston Physician Dr. Rodolfo Giraldi Establishes National Scholarship to Cultivate the Next Generation of Medical Practitioners - Cantech Letter
Journey Medical Corporation Announces FDA Approval and Efficacy Results of Emrosi for Rosacea Treatment at 2025 Fall Clinical Dermatology Conference - Quiver Quantitative
Journey Medical (NASDAQ: DERM) Phase 3 pooled data: Emrosi cut lesions by 19.2 - Stock Titan
Fortress Biotech, Inc. (FBIO) Stock Price, News, Quote & History - Yahoo
Journey Medical Corporation (DERM) Stock forecasts - Yahoo
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.18%
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):